The LYCRA Company Launches LYCRA EnviroFit™ Fiber at INDEX™ 23
13.4.2023 12:00:00 EEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the personal care and apparel industries, is exhibiting its newest fiber innovations for hygiene and personal care products at INDEX™ 23, the world’s leading nonwovens exhibition, which takes place at Palexpo in Geneva, Switzerland, April 18 – 21.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005005/en/
The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber for personal care products at INDEX™ 23, April 18 – 21. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping to conserve resources without compromising product performance. (Photo: Business Wire)
At the trade show, The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber, one of the many fibers that the company has developed as part of its Planet Agenda sustainability platform. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping conserve resources without compromising product performance.
“We are thrilled to introduce LYCRA EnviroFit™ fiber, which reduces fiber weight while maintaining the overall quality and performance that personal care products require,” said Scott Blackadar, president, personal care at The LYCRA Company. “Having less mass means fewer resources and less energy are consumed during diaper production. This fiber will appeal to manufacturers who want to significantly reduce their product’s environmental impact and help improve its carbon footprint.”
In addition to continuously improving its range of fibers for personal care products, The LYCRA Company also focuses on providing total solutions for the challenges its customers face. The company is offering two unique delivery technologies aimed at improving the spandex unwinding process and improving diaper line productivity that will also be promoted at the show.
Introducing Trio Loop Yarn Control
The LYCRA Company is showcasing the Trio Loop Technology at INDEX™ 23, the latest yarn control system from BTSR International S.p.A. Trio Loop Technology, in combination with MATRIXCUBE tension controlled plug-and-play unwinding systems, improves yarn tension control and adds more troubleshooting options to further improve diaper line productivity.
Distributing Knotter Type 093E
The LYCRA Company is also the exclusive global distributor of the new and improved Knotter Type 093E for diaper production. This breakthrough innovation by Mesdan S.p.A. offers manufacturers greater efficiency and reliability by eliminating manual knot tying and reducing machine stops.
“By offering these delivery technologies, we are demonstrating that we are a trusted and highly valued solution provider in the industry,” said Werner Hopstaken, global director, personal care at The LYCRA Company. “We are excited to offer our personal care customers these innovative products by BTSR and Mesdan and encourage them to contact us to learn more.”
Visit The LYCRA Company representatives at INDEX™ 23 stand number 2151 or visit this website to discover more benefits of these innovations.
About INDEX™ 23
INDEX™ 23 is the largest global trade show for the nonwovens market. Held every three years, it attracts thousands of visitors from over 100 countries in every region. In addition to its exhibit space, INDEX™ hosts free industry workshops, seminars, tutorials, and presentations during the show. For more information, visit indexnonwovens.com.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, marketing support, and LYCRA ONE™ marketplace. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
LYCRA EnviroFit™ is a trademark of The LYCRA Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005005/en/
Contact information
Werner Hopstaken
werner.hopstaken@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom